Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs Findings suggest TUS will demonstrate broad antileukemic activity across AML patients TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS ...

Core Viewpoint - Aptose Biosciences Inc. has successfully closed a public offering, raising $8 million through the sale of 40 million common shares at $0.20 each, along with warrants for an additional 20 million shares [1]. Group 1: Offering Details - The public offering included 40,000,000 common shares priced at $0.20 per share and warrants to purchase up to 20,000,000 common shares at an exercise price of $0.25 per share, which are exercisable immediately and will expire in five years [1]. - The offering was conducted by A.G.P./Alliance Global Partners as the sole placement agent [2]. - The gross proceeds from the offering amounted to $8 million before deducting fees and expenses [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [1]. Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5]. - The company's lead product, tuspetinib (TUS), is an oral kinase inhibitor that has shown efficacy as both a monotherapy and in combination therapy for patients with relapsed or refractory acute myeloid leukemia (AML) [5].

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its "reasonable best efforts" public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of up to 40,000,000 shares of common stock and warrants to ...

TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populationsStudy execution update is expected during ASH 2024 SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differenti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporatio ...

Financial Performance - Aptose reported a net loss of $6.95 million for Q3 2024, a decrease of $4.5 million compared to a net loss of $11.45 million in Q3 2023[9]. - Research and development expenses for Q3 2024 were $4.7 million, down from $8.3 million in Q3 2023, reflecting a decrease of $3.6 million[11]. - Total cash and cash equivalents as of September 30, 2024, were $8 million, providing sufficient resources to fund operations through January 2025[10]. - The accumulated deficit as of September 30, 2024, was $539.4 million, compared to $515.5 million at the end of 2023[10]. Clinical Development - Tuspetinib demonstrated broad clinical activity in AML patients during the APTIVATE trial, achieving responses in patients with diverse mutation profiles, including those with adverse genetics[3]. - The company plans to initiate dosing of the TUS+VEN+AZA triplet therapy in newly diagnosed AML patients in Q4 2024[7]. - Program costs for tuspetinib were $4.1 million for Q3 2024, down from $5.8 million in Q3 2023, primarily due to reduced clinical trial activity[12]. - Aptose is negotiating a new co-development collaboration agreement with Hanmi to accelerate the clinical development of tuspetinib[3]. - The company is focused on clinical development plans and the therapeutic potential of tuspetinib[15]. - The progress of clinical trials is a key factor influencing future performance[16]. - The company is exploring partnerships to enhance its clinical development efforts[16]. Compliance and Regulatory Issues - The company is addressing compliance issues with Nasdaq regarding stockholders' equity and minimum bid price requirements[6]. - The company is working on a compliance plan to regain Nasdaq compliance[15]. - There are risks associated with early-stage drug development, including demonstrating efficacy and regulatory approval processes[16]. Capital and Funding - The company is actively seeking capital to fund its research and operations[16]. - The company received a $10 million loan from Hanmi Pharmaceutical to support the development of tuspetinib, convertible into milestone obligations under a future collaboration agreement[3]. Forward-Looking Statements - The company does not intend to update forward-looking statements unless required by law[17]. - Investors are cautioned that forward-looking statements are not guarantees of future performance[17]. Market Conditions - There are uncertainties related to market and economic conditions that could impact results[16]. - The company aims to attract and retain key personnel for its operations[16].

SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended September 30, 2024, and provided a corporate update. "Triple drug therapies (triplets) that build on the standard of care in AML have yielded higher response rates yet are limited to ...

Core Viewpoint - Aptose Biosciences Inc. held a special meeting of shareholders on September 5, 2024, where key proposals regarding the issuance of common shares and potential adjournments were approved by the requisite number of votes [1]. Proposal Summary - Proposal No. 1: Approval of the issuance of common shares underlying certain warrants was passed with 3,969,105 votes in favor, representing 93.34% of the votes cast [3]. - Proposal No. 2: Approval for one or more adjournments of the meeting was also passed, with 97.05% of votes in favor [3]. Voting Results - A total of 6,052,460 common shares were voted, accounting for 33.42% of the issued and outstanding shares [1][3]. - The breakdown of votes for Proposal No. 1 included 3,969,105 votes for, 267,013 against, and 16,342 withheld/abstained [3]. - The total shares issued and outstanding were reported as 18,109,393, with 1,800,000 shares held by insiders excluded from the voting results [3]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The lead compound, tuspetinib, is an oral kinase inhibitor targeting acute myeloid leukemia (AML) and is being developed for both monotherapy and combination therapy [4].

Core Insights - Aptose Biosciences Inc. has secured a $10 million loan from Hanmi Pharmaceutical Co. Ltd. to support the development of tuspetinib, an oral kinase inhibitor for acute myeloid leukemia (AML) [1][2] - The loan can be converted into prepayment of milestone obligations or repaid after the completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients [1] - Aptose and Hanmi are negotiating a new co-development collaboration agreement to provide additional funding for the clinical development of tuspetinib [2] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib, has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML, and is being developed as a frontline triplet therapy for newly diagnosed AML [3]

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m. (ET), without business being considered, due to a lack of quorum. At the t ...